当前位置：
X-MOL 学术
›
Dermatitis
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up.
Dermatitis ( IF 5.2 ) Pub Date : 2023-10-26 , DOI: 10.1089/derm.2023.0220 Francisco José Navarro-Triviño 1 , Manuel Galán-Gutiérrez 2 , José Carlos-Armario Hita 3 , Ricardo Ruiz-Villaverde 1 , Javier Domínguez-Cruz 4 , José Juan Pereyra-Rodríguez 4
Dermatitis ( IF 5.2 ) Pub Date : 2023-10-26 , DOI: 10.1089/derm.2023.0220 Francisco José Navarro-Triviño 1 , Manuel Galán-Gutiérrez 2 , José Carlos-Armario Hita 3 , Ricardo Ruiz-Villaverde 1 , Javier Domínguez-Cruz 4 , José Juan Pereyra-Rodríguez 4
Affiliation
Background: Hand-foot eczema (HFE) are special locations of dermatitis, which are often associated with atopic dermatitis (AD) and have a significant negative impact on the quality of life, demanding a clinically relevant improvement. Objectives: To evaluate the effectiveness and safety of dupilumab in the treatment of eczema localized in hands and/or feet in patients with moderate-to-severe AD. Methods: Retrospective multicenter study of adult patients with HFE treated with dupilumab for their AD. Patients with other concomitantly systemic immunosuppressive treatments did not undergo a washout period. The severity of palmar and/or plantar involvement was assessed using the Physician Global Assessment (PGA) scale on a scale of 0 ( = clear) to 5 ( = very severe). Eczema Area and Severity Index (EASI) and NRS-pruritus scales were also evaluated. One hundred percent of patients reached week 16, while 67/84 reached week 52 of follow-up. Results: A total of 84 patients were included 86.69% of patients showed a reduction in PGA-Hand, and 80.34% in PGA-Foot at week 52, EASI improvement was reached by 83.55% of patients at week 16 and 87.35% at week 52. Reduction of pruritus (≥4 points in NRS-pruritus scale) was 73.01% at week 16 and 80.67% at week 52. No differences in response to dupilumab were observed in the different subtypes of palmo-plantar dermatitis. Conclusions: The results obtained in our study suggest that dupilumab may be an effective and safe therapeutic option for the treatment of dermatitis localized in hands and/or feet.
中文翻译：
Dupilumab 治疗中重度特应性皮炎患者慢性掌跖湿疹的真实临床经验：52 周随访。
背景：手足湿疹（HFE）是特殊部位的皮炎，通常与特应性皮炎（AD）相关，对生活质量产生显着的负面影响，需要临床相关的改善。目的：评估 dupilumab 治疗中重度 AD 患者手部和/或足部局部湿疹的有效性和安全性。方法：对接受 dupilumab 治疗 AD 的成年 HFE 患者进行回顾性多中心研究。同时接受其他全身免疫抑制治疗的患者没有经历清除期。使用医师总体评估 (PGA) 量表评估手掌和/或足底受累的严重程度，评分范围为 0（= 明确）至 5（= 非常严重）。还评估了湿疹面积和严重程度指数 (EASI) 以及 NRS 瘙痒量表。100% 的患者到达随访第 16 周，而 67/84 的患者到达随访第 52 周。结果：共纳入 84 名患者，第 52 周时，86.69% 的患者显示 PGA-Hand 减少，80.34% 的患者显示 PGA-Foot 减少，83.55% 的患者在第 16 周时达到 EASI 改善，87.35% 的患者在第 52 周时达到改善第 16 周时瘙痒减轻（NRS 瘙痒量表≥4 分）为 73.01%，第 52 周时为 80.67%。在不同亚型的掌跖皮炎中，未观察到对 dupilumab 的反应存在差异。结论：我们的研究结果表明，dupilumab 可能是治疗手和/或脚局部皮炎的有效且安全的治疗选择。
更新日期：2023-10-26
中文翻译：
Dupilumab 治疗中重度特应性皮炎患者慢性掌跖湿疹的真实临床经验：52 周随访。
背景：手足湿疹（HFE）是特殊部位的皮炎，通常与特应性皮炎（AD）相关，对生活质量产生显着的负面影响，需要临床相关的改善。目的：评估 dupilumab 治疗中重度 AD 患者手部和/或足部局部湿疹的有效性和安全性。方法：对接受 dupilumab 治疗 AD 的成年 HFE 患者进行回顾性多中心研究。同时接受其他全身免疫抑制治疗的患者没有经历清除期。使用医师总体评估 (PGA) 量表评估手掌和/或足底受累的严重程度，评分范围为 0（= 明确）至 5（= 非常严重）。还评估了湿疹面积和严重程度指数 (EASI) 以及 NRS 瘙痒量表。100% 的患者到达随访第 16 周，而 67/84 的患者到达随访第 52 周。结果：共纳入 84 名患者，第 52 周时，86.69% 的患者显示 PGA-Hand 减少，80.34% 的患者显示 PGA-Foot 减少，83.55% 的患者在第 16 周时达到 EASI 改善，87.35% 的患者在第 52 周时达到改善第 16 周时瘙痒减轻（NRS 瘙痒量表≥4 分）为 73.01%，第 52 周时为 80.67%。在不同亚型的掌跖皮炎中，未观察到对 dupilumab 的反应存在差异。结论：我们的研究结果表明，dupilumab 可能是治疗手和/或脚局部皮炎的有效且安全的治疗选择。
京公网安备 11010802027423号